Press Releases

INCLINE VILLAGE, Nev. , Feb. 3, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has entered into an agreement with Genentech, Inc. ( Genentech ) and F. Hoffmann-La Roche Ltd. (Roche) which resolves all outstanding legal disputes between the parties, including

-- Dividend Amount of $0.15 per Share per Quarter --
-- Decision to Continue Operations is in the Best Interest of its Shareholders --

INCLINE VILLAGE, Nev. , Dec. 12, 2013 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 12, 2013, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 5, 2013, the record date.

INCLINE VILLAGE, Nev. , Dec. 10, 2013 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2013, of approximately $109 million , as compared with actual revenue of $86 million for the fourth quarter of 2012, an

INCLINE VILLAGE, Nev. , Dec. 4, 2013 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the adjusted conversion rate for the: 3.75% Convertible Senior Notes due May 1, 2015 ( May 2015 Notes), is 159.9165 shares of common stock per $1,000 principal amount or approximately

INCLINE VILLAGE, Nev. , Dec. 2, 2013 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, is scheduled to present at the 25 th Annual Piper Jaffray Healthcare Conference in New York tomorrow,

INCLINE VILLAGE, Nev. , Nov. 7, 2013 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, will present at the following upcoming conferences. (Logo:

--Revenues Increased 14 Percent--

INCLINE VILLAGE, Nev. , Nov. 6, 2013 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it closed a financing transaction with Durata Therapeutics, Inc. (NASDAQ: DRTX), a pharmaceutical company focused on the development and commercialization of novel therapeutics for

INCLINE VILLAGE, Nev. , Nov. 5, 2013 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company has entered into a debt financing transaction with Direct Flow Medical, Inc. (DFM), a transcatheter heart valve innovator focused on improving patient outcomes.  PDL will

INCLINE VILLAGE, Nev. , Oct. 28, 2013 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2013 financial results for the period ended September 30, 2013 , on Wednesday, November 6, 2013 , after market close.

INCLINE VILLAGE, Nev. , Oct. 21, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed (NASDAQ: DEPO) in exchange for a $240.5 million cash

INCLINE VILLAGE, Nev. , Oct. 2, 2013 /PRNewswire/ --  PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it closed a financing transaction with LENSAR, Inc. , a leader in next-generation femtosecond laser technology for refractive cataract surgery, in which PDL will provide LENSAR with

INCLINE VILLAGE, Nev. , Sept. 12, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the September 12, 2013 , regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of September 5, 2013 , the record date.

INCLINE VILLAGE, Nev. , Sept. 11, 2013 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin , the company's president and chief executive officer, is scheduled to present at the 4 th Annual Credit Suisse Small/Mid Cap Conference in New York City on